Search results for "Prom"

showing 10 items of 2286 documents

Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemothe…

2010

Purpose We analyzed the incidence, risk factors, and outcome of therapy-related myeloid neoplasms (t-MNs) in patients with acute promyelocytic leukemia (APL) in first complete remission (CR). Patients and Methods From 1996 to 2008, 1,025 patients with APL were enrolled onto three sequential trials (LPA96, LPA99, and LPA2005) of the Programa Español para el Tratamiento de Enfermedades Hematológicas and received induction and consolidation therapy with all-trans-retinoic acid (ATRA) and anthracycline-based chemotherapy. Results Seventeen of 918 patients who achieved CR developed t-MN (10 with < 20% and seven with ≥ 20% of bone marrow blasts) after a median of 43 months from CR. Partial and…

Acute promyelocytic leukemiaAdultMaleCancer Researchmedicine.medical_specialtyMyeloidAnthracyclinemedicine.medical_treatmentTretinoinGastroenterologyLeukemia Promyelocytic AcuteTretinoinRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCumulative incidenceAnthracyclinesProspective StudiesAgedChemotherapybusiness.industryIncidenceNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisSurgeryLeukemiamedicine.anatomical_structureTreatment OutcomeOncologyFemaleBone marrowbusinessBone Marrow Neoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

Acute Promyelocytic Leukemia during Pregnancy: A Systematic Review of the Literature

2020

The management of pregnant women with acute promyelocytic leukemia (APL) is a challenging situation where limited evidence-based information is available. We performed a systematic literature review to analyze the outcomes reported for both mother and fetus when APL is diagnosed during pregnancy. PubMed, Scopus and Web of Science databases were systematically searched to identify studies reporting cases of APL during pregnancy. Sixty-six articles met the eligibility criteria (53 single case reports). Ninety-two patients were eligible for induction therapy, with most them being treated with all-trans retinoic acid alone (32%) or combined with chemotherapy (43%), while the remaining patients …

Acute promyelocytic leukemiaCancer Researchmedicine.medical_specialtyAbortionchemotherapylcsh:RC254-282Article03 medical and health sciences0302 clinical medicineObstetrics and gynaecologymedicineNeonatologyPregnancyFetal viabilityRespiratory distressObstetricsbusiness.industryGestational ageacute promyelocytic leukemialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseall-trans retinoic acidarsenic trioxideOncology030220 oncology & carcinogenesispregnancybusiness030215 immunologyCancers
researchProduct

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup …

2016

Abstract Background: Standard therapy of acute promyelocytic leukemia has long relied on the combination of All-trans-retinoic acid (ATRA) and chemotherapy. The introduction of arsenic trioxide (ATO) in APL treatment has allowed achievement of similarly high remission and survival rates coupled with significantly reduced myelosuppression. Recent results of the APL0406 trial by the GIMEMA-AMLSG-SAL study groups showed that the combination of ATRA and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in front-line therapy of low/intermediate risk acute promyelocytic leukemia (APL). The implications of these results for the clinical practice of APL patients in Germany …

Acute promyelocytic leukemiaChemotherapyPediatricsmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyComplete remissionCell BiologyHematologymedicine.diseaseBiochemistryChemotherapy regimenRegimenchemistry.chemical_compoundchemistryMedicineCumulative incidenceObservational studyArsenic trioxidebusinessneoplasmsBlood
researchProduct

Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants.

2020

Acute promyelocytic leukemia (APL) is a special disease entity of acute myeloid leukemia (AML). The clinical use of all-trans retinoic acid (ATRA) has transformed APL into the most curable form of AML. The majority of APL cases are characterized by the fusion gene PML-RARA. Although the PML-RARA fusion gene can be detected in almost all APL cases, translocation variants of APL have been reported. To date, this is the most comprehensive review of these translocations, discussing 15 different variants. Reviewed genes involved in APL variants include: ZBTB16, NPM, NuMA, STAT5b, PRKAR1A, FIP1L1, BCOR, NABP1, TBLR1, GTF2I, IRF2BP2, FNDC3B, ADAMDTS17, STAT3, and TFG. The genotypic and phenotypic …

Acute promyelocytic leukemiaGenotypeSTAT5BChromosomal translocationFusion geneslcsh:RC254-282Translocation GeneticFusion gene03 medical and health sciences0302 clinical medicineLeukemia Promyelocytic AcuteAcute promyelocytic leukemiaimmune system diseasesMedicineHumansneoplasmsPRKAR1AGeneRARAlcsh:RC633-647.5business.industryMyeloid leukemialcsh:Diseases of the blood and blood-forming organsHematologyGeneral Medicinelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseFusion proteinNeoplasm ProteinsOncology030220 oncology & carcinogenesisCancer researchbusinessChimeric proteins030215 immunologyHematology/oncology and stem cell therapy
researchProduct

First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic…

2017

Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low-risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis.

Acute promyelocytic leukemiaMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentMedizinTretinoinGastroenterologyArsenicals03 medical and health scienceschemistry.chemical_compound0302 clinical medicineArsenic TrioxideLeukemia Promyelocytic AcuteTretinoinInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRetinoidArsenic trioxideChildneoplasmsParesisRetrospective StudiesChemotherapybusiness.industryStandard treatmentInfantPosterior reversible encephalopathy syndromeOxidesHematologymedicine.diseaseSurgeryTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemalemedicine.symptombusiness030215 immunologymedicine.drug
researchProduct

Prognostic Factors in APL

2018

The prognosis of acute promyelocytic leukemia (APL) has significantly improved since the introduction of anthracyclines, but especially after the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). The identification of prognostic factors is a key process in clinical investigation, since their recognition allows the stratification of disease risks and promotes refined therapeutic adjustments. In fact, most treatments are now designed following risk-adapted strategies in order to optimize the therapeutic efficacy and minimizing side effects. The efficacy of treatment is one major determinant in prognosis. Therefore, the impact of a number of disease and patient characteristi…

Acute promyelocytic leukemiaOncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentDiseasemedicine.diseasePredictive valueClinical trialchemistry.chemical_compoundchemistryClinical investigationInternal medicinemedicineRelapse riskArsenic trioxidebusiness
researchProduct

Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia

2013

Abstract Background Cyto- and molecular-genetic abnormalities evaluated at initial diagnosis are the most powerful prognostic and in part also predictive markers in acute myeloid leukemia (AML) with regard to achievement of complete remission (CR) and survival. Nonetheless, after relapse the prognostic impact of clinical characteristics and genetic abnormalities assessed at initial diagnosis with respect to achievement of subsequent CR and survival are less clear. Aims To evaluate the probability of CR achievement and survival in relapsed AML patients in correlation to clinical characteristics and genetic abnormalities assessed at initial diagnosis as well as treatment strategy. Methods The…

Acute promyelocytic leukemiaOncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentImmunologySalvage therapyCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseasePomalidomideBiochemistryChemotherapy regimenSurgeryInternal medicineCEBPACytarabineMedicinebusinessmedicine.drugBlood
researchProduct

Myeloid sarcoma of the oral cavity : a case report and review of 89 cases from the literature

2017

Myeloid sarcoma is a tumor mass of immature myeloid or granulocytic cells that affects extramedullary anatomic sites, including uncommonly the oral cavity. A 24-year-old female was referred for evaluation of a fast growing painful gingival swelling lasting 2 weeks, associated with fever, fatigue, and cervical lymphadenopathy. Intraoral examination showed a bluish swelling on the right posterior lower gingiva exhibiting necrotic surface. Incisional biopsy of the gingival lesion displayed diffuse infiltration of undifferentiated tumor cells with granulocytic appearance, strongly immunopositive for CD99, myeloperoxidase and Ki-67 (60%), and negative for CD20, CD3, CD34 and TdT. Blood tests pre…

Acute promyelocytic leukemiaPathologymedicine.medical_specialtyMyeloidOral Medicine and Pathologybusiness.industryCD99CD34Myeloid leukemiaCase Report030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Pancytopenia03 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesishemic and lymphatic diseasesUNESCO::CIENCIAS MÉDICASMyeloid sarcomaMedicineSarcomabusinessGeneral Dentistry
researchProduct

Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia - Updated Results of the Ital…

2014

Abstract Background: We recently showed that the combination of ATRA and arsenic trioxide (ATO) is at least not inferior and possibly superior to standard ATRA and chemotherapy (CHT) in the front-line management of low/intermediate risk APL (Italian-German APL 0406 trial; Lo-Coco et al., NEJM 2013). We report herein on the extended and final series of 276 patients (162 were in the previous report) with the last case being enrolled into the study in January 2013. Methods: The APL0406 study was a prospective, open-label, randomized intergroup trial conducted by the Italian GIMEMA and the German SAL and AMLSG study groups. Eligible patients were adults aged 18-<71 years with newly diagnosed…

Acute promyelocytic leukemiaPediatricsmedicine.medical_specialtyChemotherapyAnthracyclinebusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologyOff-label usemedicine.diseaseBiochemistrychemistry.chemical_compoundchemistryInternal medicineCohortmedicineIdarubicinCumulative incidenceArsenic trioxidebusinessmedicine.drug
researchProduct

Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study

2015

Abstract Background: Acute promyelocytic leukemia (APL) is a rare subtype of childhood acute myeloid leukemia (AML). Bleeding complications occur in 80% of patients at diagnosis and contribute to a higher incidence of early death (ED) in APL compared to other AML subtypes. However, estimates of ED in pediatric APL are imprecise and factors associated with ED in children with APL are unknown. Objectives: To determine the incidence and predictors of ED, defined as death within 60 days from presentation, in childhood APL. Methods: We conducted a retrospective international analysis of children diagnosed with APL between January 1993 and December 2013. The study included 236 patients from the I…

Acute promyelocytic leukemiaPediatricsmedicine.medical_specialtybusiness.industryIncidence (epidemiology)ImmunologyChildhood Acute Myeloid LeukemiaRetrospective cohort studyCell BiologyHematologyOdds ratiomedicine.diseaseBiochemistryClinical trialmedicinebusinessBody mass indexLung allocation scoreBlood
researchProduct